famotidine has been researched along with Infections, Helicobacter in 65 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "Two hundred patients with duodenal ulcer were randomly divided into the treated group treated with JWC, 160 mg 3 times per day and the control group treated with famotidine 20 mg twice per day, both by orally taking before meal for 4 weeks, 100 cases in each group." | 9.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 9.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 9.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 9.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 9.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 6.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Famotidine cannot decrease the incidence of peptic ulcer or ulcer bleeding in thienopyridine users with atherosclerotic disease and a history of peptic ulcer." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22." | 5.16 | Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. ( Amemoto, K; Ashida, K; Esaki, H; Fukuchi, T; Hashimoto, T; Isowa, G; Kiyota, K; Majima, K; Morikawa, H; Murotani, M; Ohyama, Y; Oka, H; Sakaguchi, M; Takao, F; Takao, M; Yamashita, H, 2012) |
| " We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "Two hundred patients with duodenal ulcer were randomly divided into the treated group treated with JWC, 160 mg 3 times per day and the control group treated with famotidine 20 mg twice per day, both by orally taking before meal for 4 weeks, 100 cases in each group." | 5.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 5.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 5.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "Low-dose lansoprazole is more effective than full-dose famotidine for the control of symptoms in patients with gastro-oesophageal reflux disease, and H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| " pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b." | 5.09 | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. ( Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H, 1999) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 5.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 5.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " pylori-positive and 10-negative subjects) with 100 mg aspirin plus 75 mg clopidogrel (AC) once-daily dosing and AC plus 20 mg famotidine twice-daily dosing (ACH)." | 2.79 | Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. ( Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 2.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy." | 2.72 | Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. ( Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K, 2006) |
| "Famotidine was administered after lunch and before sleep, and the others were after breakfast and dinner." | 2.71 | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. ( Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M, 2005) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| "Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs." | 1.34 | Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. ( Fukui, H; Takakura, Y; Yajima, H; Yamao, J, 2007) |
| "Treatment with amoxicillin, metronidazole, and famotidine may not be effective in eradicating gastric infections with Helicobacter spp in dogs." | 1.30 | Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs. ( Cornetta, AM; Gleed, RD; McDonough, PL; Simpson, KW; Strauss-Ayali, D, 1998) |
| "Hyperemesis gravidarum is the most severe spectrum of gastrointestinal complaints in pregnant women." | 1.30 | Helicobacter pylori infection and persistent hyperemesis gravidarum. ( Jacoby, EB; Porter, KB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (36.92) | 18.2507 |
| 2000's | 35 (53.85) | 29.6817 |
| 2010's | 5 (7.69) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Ragab, MAA | 2 |
| Maher, HM | 2 |
| Tarek, S | 2 |
| Mahgoub, H | 2 |
| Uotani, T | 1 |
| Sugimoto, M | 4 |
| Nishino, M | 1 |
| Ichikawa, H | 1 |
| Sahara, S | 1 |
| Yamade, M | 1 |
| Iwaizumi, M | 1 |
| Yamada, T | 1 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Umemura, K | 1 |
| Watanabe, H | 1 |
| Miyajima, H | 2 |
| Furuta, T | 4 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 1 |
| Lai, KH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Hawkey, CJ | 1 |
| Taha, AS | 1 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Lam, KF | 1 |
| Chu, WM | 1 |
| Chan, P | 1 |
| Ling, YH | 1 |
| Kng, C | 1 |
| Yuen, WC | 1 |
| Lau, YK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Murakami, K | 2 |
| Okimoto, T | 2 |
| Kodama, M | 2 |
| Tanahashi, J | 1 |
| Mizukami, K | 1 |
| Shuto, M | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Fujioka, T | 2 |
| Sakaguchi, M | 1 |
| Takao, M | 1 |
| Ohyama, Y | 1 |
| Oka, H | 1 |
| Yamashita, H | 1 |
| Fukuchi, T | 1 |
| Ashida, K | 1 |
| Murotani, M | 2 |
| Majima, K | 1 |
| Morikawa, H | 1 |
| Hashimoto, T | 2 |
| Kiyota, K | 1 |
| Esaki, H | 1 |
| Amemoto, K | 1 |
| Isowa, G | 1 |
| Takao, F | 1 |
| Mak, SK | 1 |
| Loo, CK | 1 |
| Wong, AM | 1 |
| Wong, PN | 1 |
| Lo, KY | 1 |
| Tong, GM | 1 |
| Lam, EK | 1 |
| Wong, AK | 1 |
| Adachi, K | 5 |
| Fujishiro, H | 3 |
| Mihara, T | 4 |
| Komazawa, Y | 4 |
| Kinoshita, Y | 5 |
| Ono, M | 2 |
| Kawamura, A | 1 |
| Liu, CC | 1 |
| Lee, CL | 1 |
| Chan, CC | 1 |
| Tu, TC | 1 |
| Liao, CC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Kirika, NV | 1 |
| Bodrug, NI | 1 |
| Butorov, IV | 1 |
| Butorov, SI | 1 |
| Graham, DY | 1 |
| Opekun, AR | 1 |
| Jogi, M | 1 |
| Yamaoka, Y | 1 |
| Lu, H | 2 |
| Reddy, R | 1 |
| El-Zimaity, HM | 1 |
| Fujisawa, T | 1 |
| Azumi, T | 1 |
| Katsube, T | 1 |
| Furuta, K | 2 |
| Kazumori, H | 1 |
| Nomura, S | 1 |
| Suzuki, H | 2 |
| Masaoka, T | 1 |
| Kurabayashi, K | 1 |
| Ishii, H | 2 |
| Kitajima, M | 1 |
| Nomoto, K | 1 |
| Hibi, T | 2 |
| Okudaira, K | 2 |
| Shirai, N | 3 |
| Miura, S | 2 |
| Scarpignato, C | 1 |
| Fujiwara, Y | 1 |
| Higuchi, K | 1 |
| Nebiki, H | 1 |
| Chono, S | 1 |
| Uno, H | 1 |
| Kitada, K | 1 |
| Satoh, H | 1 |
| Nakagawa, K | 1 |
| Kobayashi, K | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Oshitani, N | 1 |
| Arakawa, T | 1 |
| Kamada, T | 1 |
| Hata, J | 1 |
| Kusunoki, H | 1 |
| Sugiu, K | 1 |
| Ito, M | 1 |
| Tanaka, S | 1 |
| Kawamura, Y | 1 |
| Chayama, K | 1 |
| Haruma, K | 1 |
| Ishihara, S | 2 |
| Amano, Y | 1 |
| Hattori, S | 1 |
| Ji, F | 1 |
| Chen, JY | 1 |
| Chen, JX | 1 |
| Gon, S | 1 |
| Irie, Y | 1 |
| Takahashi, M | 1 |
| Sato, R | 1 |
| Inoue, K | 1 |
| Watanabe, K | 1 |
| Otsu, S | 1 |
| Ikuma, M | 1 |
| Hishida, A | 1 |
| Ishizaki, T | 1 |
| Fukuda, M | 2 |
| Shirasaka, D | 1 |
| Aoyama, N | 1 |
| Miki, I | 1 |
| Kachi, M | 1 |
| Morita, Y | 1 |
| Tamura, T | 1 |
| Kasuga, M | 1 |
| Spasov, AA | 1 |
| Chernikov, MV | 1 |
| Speranskaia, AS | 1 |
| Zaĭchenko, SI | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Yajima, H | 1 |
| Yamao, J | 1 |
| Fukui, H | 1 |
| Takakura, Y | 1 |
| Borody, TJ | 1 |
| Andrews, P | 1 |
| Fracchia, G | 1 |
| Brandl, S | 1 |
| Shortis, NP | 1 |
| Bae, H | 1 |
| Tsuji, S | 1 |
| Kawano, S | 1 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Tatsumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Noguchi, M | 1 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Takahashi, Y | 1 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 1 |
| Mizuno, M | 1 |
| Maeda, S | 1 |
| Gschwantler, M | 3 |
| Weiss, W | 3 |
| Penka, G | 1 |
| Zirm, B | 1 |
| Stupnicki, T | 1 |
| Spath, P | 1 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 1 |
| Mégraud, F | 1 |
| Guerre, J | 1 |
| Elouaer-Blanc, L | 1 |
| Dominguez, HL | 1 |
| Freston, JW | 1 |
| Parasakthi, N | 2 |
| Goh, KL | 3 |
| Lin, JT | 1 |
| Wang, JT | 1 |
| Wu, MS | 1 |
| Lee, WY | 1 |
| Yang, JC | 1 |
| Wang, TH | 1 |
| Casini, A | 1 |
| Pizzigallo, AM | 1 |
| Mari, F | 1 |
| Bertol, E | 1 |
| Surrenti, C | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Navaratnam, P | 1 |
| Peh, SC | 1 |
| Wong, NW | 1 |
| Chuah, SY | 2 |
| Rahman, NA | 1 |
| Lo, YL | 1 |
| Gladziwa, U | 1 |
| Klotz, U | 1 |
| Moayyedi, P | 1 |
| Toetsch, M | 1 |
| Suzuki, M | 1 |
| Mori, M | 1 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Dogăn, UB | 1 |
| Tunçer, C | 1 |
| Dursun, A | 1 |
| Kandilci, U | 1 |
| Das, UN | 1 |
| Cornetta, AM | 1 |
| Simpson, KW | 1 |
| Strauss-Ayali, D | 1 |
| McDonough, PL | 1 |
| Gleed, RD | 1 |
| Dragosics, B | 2 |
| Wurzer, H | 2 |
| Brandstätter, G | 2 |
| Kanayama, S | 1 |
| Jacoby, EB | 1 |
| Porter, KB | 1 |
| Sugano, K | 2 |
| Sasakii, M | 1 |
| Joh, T | 1 |
| Yokoyama, Y | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Itoh, M | 1 |
| Schütze, K | 1 |
| Hirschl, AM | 1 |
| Pasching, E | 1 |
| Wimmer, M | 1 |
| Klimpfinger, M | 1 |
| Oberhuber, G | 1 |
| Hentschel, E | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Yoshida, N | 1 |
| Yoshikawa, T | 1 |
| Tanaka, Y | 1 |
| Fujita, N | 1 |
| Kassai, K | 1 |
| Naito, Y | 1 |
| Kondo, M | 1 |
| Mansurova, FKh | 1 |
| Kadyrov, DM | 1 |
| Odinaev, RI | 1 |
| Ishankulova, DM | 1 |
| Icatlo, FC | 1 |
| Kimura, N | 1 |
| Goshima, H | 1 |
| Kodama, Y | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Sasaki, N | 1 |
| Taniyama, K | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 1 |
| Hu, PJ | 1 |
| Cui, Y | 1 |
| Tytgat, GN | 1 |
| See, MC | 1 |
| Birnbaum, AH | 1 |
| Schechter, CB | 1 |
| Goldenberg, MM | 1 |
| Benkov, KJ | 1 |
| Radwan, P | 1 |
| Grodzieński, R | 1 |
| Zaorska-Rajca, J | 1 |
| Skrzydło-Radomańska, B | 1 |
| Słomka, M | 1 |
| Wysokiński, A | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Mutoh, H | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Kawauchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
5 reviews available for famotidine and Infections, Helicobacter
| Article | Year |
|---|---|
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2005 |
Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Fatty Acids, Unsaturated; Helicobacter Infections; He | 1998 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 1999 |
[Duodenal ulcer].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; | 2002 |
39 trials available for famotidine and Infections, Helicobacter
| Article | Year |
|---|---|
Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Topics: Adult; Anti-Ulcer Agents; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy | 2014 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Topics: Aged; Alcohol Drinking; Anti-Ulcer Agents; Drug Administration Schedule; Famotidine; Female; Helicob | 2011 |
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzamides; Dyspepsia; Esop | 2012 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Nega | 2003 |
Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Topics: Adult; Biomarkers; Cross-Over Studies; Drug Tolerance; Famotidine; Gastric Acidity Determination; Ga | 2003 |
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Carbolines; Clarithromycin; Drug Therapy, Co | 2003 |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug | 2004 |
Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.
Topics: Acetamides; Adult; Ambulatory Care; Circadian Rhythm; Cross-Over Studies; Cross-Sectional Studies; D | 2004 |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2005 |
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacte | 2005 |
Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Ulcer Agents; Famotidine; Female; Gastric Acid; Gastritis; H | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
[Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Duoden | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Topics: Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C1 | 2006 |
No significant difference in neutrophil activation found among three H2RAs.
Topics: Acetamides; Adult; Dyspepsia; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Hist | 2007 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Eradication of Helicobacter pylori by a combination of amoxicillin and famotidine.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastritis; Helicobacter | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.
Topics: Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Famotidine; Helicobacter Infe | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer.
Topics: Adult; Alcohol Dehydrogenase; Duodenal Ulcer; Ethanol; Famotidine; Helicobacter Infections; Helicoba | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori--a randomized, double-blind comparison of a three times daily and twice daily regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antitrichomonal Agents; Double-Blind Method; Drug Resistance, | 1997 |
Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Famotidi | 1998 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resis | 1999 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Therapy, C | 2000 |
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
Topics: Abdominal Pain; Adolescent; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; Double-Blind M | 2001 |
[The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].
Topics: Adolescent; Adult; Cisapride; Drug Therapy, Combination; Dyspepsia; Famotidine; Female; Gastric Empt | 2001 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
21 other studies available for famotidine and Infections, Helicobacter
| Article | Year |
|---|---|
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
NSAIDs and aspirin: notorious or FAMOUS?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Esop | 2009 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.
Topics: Adolescent; Adult; Aged; Biopsy; Breath Tests; Citric Acid; Endoscopy, Gastrointestinal; False Negat | 2004 |
Effect of dietary anti-urease immunoglobulin Y on Helicobacter pylori infection in Mongolian gerbils.
Topics: Animals; Anti-Ulcer Agents; Diet; Disease Models, Animal; Famotidine; Gastric Mucosa; Gerbillinae; H | 2005 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2006 |
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
Topics: Animals; Disease Models, Animal; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Histam | 2005 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Bone Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; End | 2007 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
Adenylate cyclase of gastric mucosa in patients with chronic renal failure.
Topics: Adenylyl Cyclases; Anti-Ulcer Agents; Cyclic AMP; Famotidine; Female; Gastric Mucosa; Gastrins; Heli | 1996 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Effect of chronic acid inhibition on duodenal bulb gastric metaplasia and Helicobacter pylori.
Topics: Adult; Case-Control Studies; Duodenal Ulcer; Duodenum; Famotidine; Female; Gastric Mucosa; Helicobac | 1998 |
Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Carbon Isotope | 1998 |
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine | 1999 |
Optimum management of mild esophagitis in Japan.
Topics: Anti-Ulcer Agents; Disease Management; Esophagitis, Peptic; Famotidine; Helicobacter Infections; Hel | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
[Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fa | 2000 |
Enhanced reduction of Helicobacter pylori load in precolonized mice treated with combined famotidine and urease-binding polysaccharides.
Topics: Animals; Anticoagulants; Dextran Sulfate; Disease Models, Animal; Drug Therapy, Combination; Famotid | 2000 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |